Skip to main content

Advertisement

SpringerLink
Log in

RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To comparatively evaluate the prognostic or predictive value of ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) gene expression in peripheral blood versus tumor tissue from patients with advanced non-small cell lung cancer (NSCLC) treated by gemcitabine/platinum chemotherapy.

Methods

A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. RRM1 and ERCC1 mRNA levels in the peripheral blood and tumor tissue were determined by real-time fluorescent quantitative PCR. The relationships between gene expression and clinical and pathological factors, response to chemotherapy as well as prognosis, were evaluated.

Results

RRM1 expression in peripheral blood and tumor tissue, but not ERCC1 expression, was found to be positively correlated (r = 0.332, 0.258; P = 0.020, 0.073; respectively). RRM1 and ERCC1 expression levels were nearly synchronous in both peripheral blood (r = 0.351; P = 0.013) and tumor tissue (r = 0.634; P < 0.001). Neither was correlated with clinical and pathological factors. Patients with low RRM1 expression in peripheral blood or low RRM1 or ERCC1 expression in tumor tissue experienced better response to chemotherapy (50.0 vs. 16.0%, 50.0 vs. 16.0%, and 54.2 vs. 12.0%; P = 0.012, 0.012, and 0.003; respectively), longer median survival (18.5 vs. 13.0 months, 18.5 vs. 12.0 months, and 19.8 vs. 12.5 months; P = 0.043, 0.014 and 0.007; respectively), and longer progression-free survival (6.0 vs. 4.0 months, 7.8 vs. 3.9 months, and 5.8 vs. 3.8 months; P = 0.044, 0.016, and 0.008; respectively). Cox multivariate regression analysis showed that ERCC1 expression in tumor tissue was independent indicator for overall survival.

Conclusions

Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Herrick J, Sclavi B (2007) Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage. Mol Microbiol 63:22–34

    Article  PubMed  CAS  Google Scholar 

  3. Bepler G, Kusmartseva I, Sharma S et al (2006) RRM1 modulated In vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24:4731–4737

    Article  PubMed  CAS  Google Scholar 

  4. Rosell R, Danenberg KD, Alberola V et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318–1325

    Article  PubMed  CAS  Google Scholar 

  5. Lee JJ, Maeng CH, Baek SK et al (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70:205–210

    Article  PubMed  Google Scholar 

  6. De Laat WL, Jaspers NG, Hoeijmakers JH (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13:768–785

    Article  PubMed  Google Scholar 

  7. Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33:565–577

    Article  PubMed  CAS  Google Scholar 

  8. Olaussen KA, Fouret P, Kroemer G (2007) ERCC1-specific immunostaining in non-small cell lung cancer. N Engl J Med 357:1559–1561

    Article  PubMed  CAS  Google Scholar 

  9. Wang X, Zhao J, Yang L et al (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small cell lung cancer. Med Oncol 27:484–490

    Article  PubMed  CAS  Google Scholar 

  10. Wang LR, Huang MZ, Zhang GB et al (2007) Phase II study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 60:601–607

    Article  PubMed  CAS  Google Scholar 

  11. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  12. Chen J, Li MW, Zhang GB et al (2010) Detection of RRM1, ERCC1 and BRCA1 gene expression in non-small cell lung cancer tissues and peripheral blood by SYBR real-time fluorescent quantitative PCR. J Zhejiang Univ Med Sci 39:628–633

    CAS  Google Scholar 

  13. Gong WY, Zhang XM, Wu JF et al (2011) RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis. Lung Cancer [Epub ahead of print]

  14. Chen S, Zhang J, Wang R et al (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63–70

    Article  PubMed  Google Scholar 

  15. Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer [Epub ahead of print]

  16. Ceppi P, Volante M, Novello S et al (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818–1825

    Article  PubMed  CAS  Google Scholar 

  17. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808

    Article  PubMed  CAS  Google Scholar 

  18. Lin L, Liu XQ, Wang WX et al (2008) Detection of gemcitabine-resistant genes expression in six lung cancer cell lines using real-time fluorogenetic quantitative PCR. Tumor 28:228–231

    CAS  Google Scholar 

  19. Li LL, Liu XQ (2010) Correlation of expression of ERCC1/RRM1 with cisplatin combined with gemcitabine chemotherapy sensitivity and prognosis in non-small cell lung cancer. Bull Acad Mil Med Sci 34:265–268, 296

    CAS  Google Scholar 

  20. Vogel U, Dybdahl M, Frentz G et al (2000) DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461:197–210

    PubMed  CAS  Google Scholar 

  21. Dong S, Wu YL, Guo AL et al (2007) Detection of expression of RRM1 mRNA by real-time fluorescent quantitative PCR in non-small cell lung cancer tissues and peripheral blood. Tumor 27:577–581

    CAS  Google Scholar 

  22. Wang LE, Yin M, Dong Q et al. (2011) DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol [Epub ahead of print]

  23. Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194–1203

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work is supported by the Science and Technology Planning Project of Zhejiang Province (No. 2009C33165), the Medical Science Research Fund Scheme of Zhejiang Province (No. 2008A060), and the Chinese Medicine General Research Program of Zhejiang Province (2009CA061).

Conflicts of interest

None of the authors have any conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qing Chun Street, Hangzhou, 310003, People’s Republic of China

    Guo Bing Zhang, Jian Chen, Lin Run Wang, Jun Li & Yang Wang

  2. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Ming Wei Li

  3. Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Nong Xu

  4. Clinical Laboratory, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Jian Zhong Shentu

Authors
  1. Guo Bing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Run Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming Wei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian Zhong Shentu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lin Run Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, G.B., Chen, J., Wang, L.R. et al. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol 69, 1277–1287 (2012). https://doi.org/10.1007/s00280-012-1834-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1834-x

Keywords

Search

Navigation